10x Genomics

Name: 10x Genomics
Brand: 10x Genomics

Powering researchers’ insights with innovative single cell, spatial biology, & in situ tools. 🧬🔬

Est 2012|65 Ref Customers

LinkedIn 288K|Web traffic 277K|FTEs 2,429|HQ Pleasanton, California, US

01Competitive Landscape

| Aspect | 10x Genomics | NanoString (CosMx/GeoMx) | Parse Biosciences (Evercode) | |--------|---------------|--------------------------|-----------------------------| | Starting Price | Not broadly published; typically quote-based for instruments/consumables. Cloud Analysis paid usage is published by the vendor under specific conditions. | Instrument pricing often quote-based; competitor materials emphasize performance comparisons. | Kit pricing often not fully public; materials emphasize scalability and multiplexing economics. | | Best For | Laboratories requiring an established single-cell ecosystem; high-throughput droplet single-cell; spatial transcriptomics (Visium) and in situ imaging (Xenium). | Spatial/in situ buyers comparing CosMx vs Xenium; users requiring specific spatial profiling or protein-detection workflows. | Very large-scale cell counts, many samples, fixation-friendly workflows, and teams optimizing for cost-per-cell and logistics without microfluidic instruments. | | Key Strength | Ecosystem, standardization, large installed base, broad assay portfolio and software pipelines. | Strong spatial positioning; competitor messaging comparing against Xenium. | Scale via split-pool combinatorial indexing; avoids reliance on droplet microfluidics instruments for certain workflows. | | Key Weakness | Perception of high kit costs; droplet workflows sensitive to sample quality; QC/analysis burden; spatial/in situ can be operationally intensive. | Competitive studies may be vendor-biased; platform choice depends heavily on tissue type, panel design, and workflow fit. | More manual steps and workflow complexity (community feedback); sequencing costs still significant; performance depends on execution. | - Direct competitors and their key differentiators - NanoString - Publishes comparative materials (e.g., CosMx SMI vs Xenium); such content is competitor-produced and should be validated with independent benchmarks. - Parse Biosciences - Positions around scalability and sample multiplexing; public-facing materials stress the ability to scale cell counts via combinatorial indexing. - Scale Biosciences - Public materials highlight lower cost-per-sample claims that should be validated in operational workflows (sample prep, sequencing, and failure rates). - Feature comparison: where 10x excels vs lags - Excels - Breadth of assay types and established workflows; many core facilities already support 10x. - Established pipeline ecosystem (Cell Ranger + Cloud Analysis option). - Lags / risks - Cost sensitivity versus combinatorial indexing (Parse/Scale) for very large projects. - In spatial/in situ, competitors may differentiate on protein capability, panel flexibility, throughput, or performance—outcomes are application-dependent. - Pricing comparison: value proposition vs alternatives - Published per-analysis pricing is available for cloud analysis from the vendor; instrument and consumable pricing is less transparent. - Alternatives may reduce capex (no droplet instrument needed) but shift costs into labor and protocol complexity. - Customer testimonials comparing 10x to competitors - Community threads discussing Parse emphasize lower reagent costs but more laboratory steps (time/labor trade-offs). - Discussions about BD Rhapsody and other alternatives appear in pricing and sustainability threads as comparative options. - Market share and adoption trends - Public perception and community commentary suggest 10x has significant recognition within the single-cell community. This is directional and not a quantified market-share statistic.

01Competitive Landscape

Aspect	10x Genomics	NanoString (CosMx/GeoMx)	Parse Biosciences (Evercode)
Starting Price	Not broadly published; typically quote-based for instruments/consumables. Cloud Analysis paid usage is published by the vendor under specific conditions.	Instrument pricing often quote-based; competitor materials emphasize performance comparisons.	Kit pricing often not fully public; materials emphasize scalability and multiplexing economics.
Best For	Laboratories requiring an established single-cell ecosystem; high-throughput droplet single-cell; spatial transcriptomics (Visium) and in situ imaging (Xenium).	Spatial/in situ buyers comparing CosMx vs Xenium; users requiring specific spatial profiling or protein-detection workflows.	Very large-scale cell counts, many samples, fixation-friendly workflows, and teams optimizing for cost-per-cell and logistics without microfluidic instruments.
Key Strength	Ecosystem, standardization, large installed base, broad assay portfolio and software pipelines.	Strong spatial positioning; competitor messaging comparing against Xenium.	Scale via split-pool combinatorial indexing; avoids reliance on droplet microfluidics instruments for certain workflows.
Key Weakness	Perception of high kit costs; droplet workflows sensitive to sample quality; QC/analysis burden; spatial/in situ can be operationally intensive.	Competitive studies may be vendor-biased; platform choice depends heavily on tissue type, panel design, and workflow fit.	More manual steps and workflow complexity (community feedback); sequencing costs still significant; performance depends on execution.

Direct competitors and their key differentiators
- NanoString
  - Publishes comparative materials (e.g., CosMx SMI vs Xenium); such content is competitor-produced and should be validated with independent benchmarks.
- Parse Biosciences
  - Positions around scalability and sample multiplexing; public-facing materials stress the ability to scale cell counts via combinatorial indexing.
- Scale Biosciences
  - Public materials highlight lower cost-per-sample claims that should be validated in operational workflows (sample prep, sequencing, and failure rates).
Feature comparison: where 10x excels vs lags
- Excels
  - Breadth of assay types and established workflows; many core facilities already support 10x.
  - Established pipeline ecosystem (Cell Ranger + Cloud Analysis option).
- Lags / risks
  - Cost sensitivity versus combinatorial indexing (Parse/Scale) for very large projects.
  - In spatial/in situ, competitors may differentiate on protein capability, panel flexibility, throughput, or performance—outcomes are application-dependent.
Pricing comparison: value proposition vs alternatives
- Published per-analysis pricing is available for cloud analysis from the vendor; instrument and consumable pricing is less transparent.
- Alternatives may reduce capex (no droplet instrument needed) but shift costs into labor and protocol complexity.
Customer testimonials comparing 10x to competitors
- Community threads discussing Parse emphasize lower reagent costs but more laboratory steps (time/labor trade-offs).
- Discussions about BD Rhapsody and other alternatives appear in pricing and sustainability threads as comparative options.
Market share and adoption trends
- Public perception and community commentary suggest 10x has significant recognition within the single-cell community. This is directional and not a quantified market-share statistic.

Aspect

10x Genomics

NanoString (CosMx/GeoMx)

Parse Biosciences (Evercode)

Starting Price

Not broadly published; typically quote-based for instruments/consumables. Cloud Analysis paid usage is published by the vendor under specific conditions.

Instrument pricing often quote-based; competitor materials emphasize performance comparisons.

Kit pricing often not fully public; materials emphasize scalability and multiplexing economics.

Best For

Laboratories requiring an established single-cell ecosystem; high-throughput droplet single-cell; spatial transcriptomics (Visium) and in situ imaging (Xenium).

Spatial/in situ buyers comparing CosMx vs Xenium; users requiring specific spatial profiling or protein-detection workflows.

Very large-scale cell counts, many samples, fixation-friendly workflows, and teams optimizing for cost-per-cell and logistics without microfluidic instruments.

Key Strength

Ecosystem, standardization, large installed base, broad assay portfolio and software pipelines.

Strong spatial positioning; competitor messaging comparing against Xenium.

Scale via split-pool combinatorial indexing; avoids reliance on droplet microfluidics instruments for certain workflows.

Key Weakness

Perception of high kit costs; droplet workflows sensitive to sample quality; QC/analysis burden; spatial/in situ can be operationally intensive.

Competitive studies may be vendor-biased; platform choice depends heavily on tissue type, panel design, and workflow fit.

More manual steps and workflow complexity (community feedback); sequencing costs still significant; performance depends on execution.

10x Genomics

01Competitive Landscape

02Market Map

01Competitive Landscape

02Market Map